Business

Best Drug Development Company

Best Drug Development Company.

articleImmupharma PlcApril 8, 20105/company/immupharma-plc/news/best-drug-development-company
Best Drug Development Company

About this update from Immupharma Plc

[{"type":"text","content":"\n RNS Number : 8786J Immupharma PLC 08 April 2010  \n \n\n\n\n\n\nFor Immediate Release\n\n\n8 April 2010\n\n\n\n\n \n \n \nImmuPharma PLC\n \n(\"ImmuPharma\")\n \nImmuPharma awarded Best Drug Development Company in Europe Award\n \nImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company, has been voted \"Best Drug Development Company, Europe\" at The New Economy Pharmaceutical & Healthcare Awards 2010. \n \nThis award follows on from two notable wins in 2009 namely; \"Best Technology Award\" at the AIM Awards, organized by the London Stock Exchange and \"Breakthrough of the year 2009\" at the European Mediscience Awards.\n \n- Ends -\n \nFor further information please contact: \n \n\n\n\n\nImmuPharma PLC\n\n\n+44 20 7152 4080\n\n\n\n\nDimitri Dimitriou, Chief Executive Officer \nRichard Warr, Chairman\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBuchanan Communications\n\n\n+44 20 7466 5000\n\n\n\n\nLisa Baderoon \nGeorge Prassas\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPanmure Gordon & Co                                                            \nAndrew Burnett\nRakesh Sharma\n\n\n+44 151 243 0963\n\n\n\n\n\n\n\n\n\n\n\n\nNoble & Company Limited\n\n\n+44 20 7763 2200\n\n\n\n\nJames Bromhead\n \n\n\n\n\n\n\n\n \nNotes to Editors:\n \nAbout ImmuPharma PLC\n \nImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders. \n \nIts lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties.  $45m in cash has been ...

More updates from Immupharma Plc